# Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.

> **NCT02598297** · PHASE3 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 49 (actual)

## Conditions studied

- Myelofibrosis With High Molecular Risk Mutations

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** Ruxolitinib Placebo

## Key facts

- **NCT ID:** NCT02598297
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-02-03
- **Primary completion:** 2017-10-23
- **Final completion:** 2017-10-23
- **Target enrollment:** 49 (ACTUAL)
- **Why stopped:** Unresolvable inability to recruit the patients.
- **Last updated:** 2019-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02598297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02598297, "Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02598297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*